Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCI | P41743 | 1/20 | 0.61 |
| ▸ | CYP2A6 | P11509 | 4/20 | 0.55 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.52 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.45 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.45 |
| ▸ | CHRNA7 | P36544 | 2/20 | 0.44 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.44 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | CDK4 | P11802 | 1/20 | 0.42 |
| ▸ | CCND1 | P24385 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL423394 | 1.00 | PRKCI (0.61) | PRKCICYP2A6MAPTRXFP1HSD11B1 | |
| SCHEMBL13786855 | 0.84 | HSD11B1 (0.55) | PRKCICYP2A6HSD11B1CHRNA7 | |
| SCHEMBL171810 | 0.82 | CYP2A6 (0.55) | PRKCICYP2A6MAPTRXFP1HSD11B1 | |
| SCHEMBL11961043 | 0.79 | HSD11B1 (0.63) | PRKCICYP2A6HSD11B1 | |
| SCHEMBL18683804 | 0.78 | PRKCI (0.60) | PRKCICYP2A6MAPTRXFP1HSD11B1 | |
| SCHEMBL16789744 | 0.76 | PRKCI (0.59) | PRKCICYP2A6MAPTHSD11B1HTR2C | |
| SCHEMBL16244710 | 0.76 | HTR2A (0.47) | PRKCICYP2A6MAPTRXFP1HTR2A | |
| SCHEMBL2114014 | 0.76 | PRKCI (0.59) | PRKCICYP2A6HSD11B1HTR2AHTR2C | |
| SCHEMBL1400341 | 0.76 | PRKCI (0.59) | PRKCICYP2A6MAPTHSD11B1HTR2C | |
| SCHEMBL20912282 | 0.76 | HTR2A (0.47) | PRKCICYP2A6MAPTRXFP1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119409615-A | 2- (Indol-3-yl) phenol compound and synthesis method thereof | 湘潭大学 | 2025-02-11 | — | — | CN | claimed |
| CN-118271331-A | Gelsemin derivatives, synthesis method and application thereof in inhibiting tumor cell proliferation | 赣江中药创新中心 | 2024-07-02 | — | — | CN | claimed |
| CN-117903161-A | Tetrathiodiindole compound and derivative, synthetic method and application thereof | 衡阳师范学院 | 2024-04-19 | — | — | CN | claimed |
| CN-116813639-A | Synthesis method of polysubstituted [1,2,3,4,5] pentathio [6,7-b ] indole and derivative | 衡阳师范学院 | 2023-09-29 | — | — | CN | claimed |
| CN-119409615-A | 2- (Indol-3-yl) phenol compound and synthesis method thereof | 湘潭大学 | 2025-02-11 | — | — | CN | disclosed |
| CN-119019310-A | Indole vinyl sulfonyl fluoride compound and preparation method thereof | 武汉理工大学 | 2024-11-26 | — | — | CN | disclosed |
| CN-115974845-B | Preparation method of Ornitinib intermediate | 奥锐特药业股份有限公司 | 2024-09-20 | — | — | CN | disclosed |
| CN-118271331-A | Gelsemin derivatives, synthesis method and application thereof in inhibiting tumor cell proliferation | 赣江中药创新中心 | 2024-07-02 | — | — | CN | disclosed |
| CN-118159533-A | Heterocyclic compounds and their use | 艾森医药有限公司 | 2024-06-07 | — | — | CN | disclosed |
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | TRI-INSTITUTIONAL THERAPEUTICS DISCOVERY INSTITUTE, INC. | 2024-04-25 | — | — | US | disclosed |
| CN-117903161-A | Tetrathiodiindole compound and derivative, synthetic method and application thereof | 衡阳师范学院 | 2024-04-19 | — | — | CN | disclosed |
| CN-117510392-A | Preparation method of bisindolyl compound | 吉林大学 | 2024-02-06 | — | — | CN | disclosed |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED | 2023-11-30 | — | — | US | disclosed |
| CN-117088890-A | Pyrrolidone-containing pyrrolidine spiro bisoxindole compound as well as preparation method and application thereof | 江苏大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-116813639-A | Synthesis method of polysubstituted [1,2,3,4,5] pentathio [6,7-b ] indole and derivative | 衡阳师范学院 | 2023-09-29 | — | — | CN | disclosed |
| CN-116621766-A | Preparation method of 3, 3-dichloro oxindole and derivative thereof | 南京林业大学 | 2023-08-22 | — | — | CN | disclosed |
| CN-115974845-A | Preparation method of oxitinib intermediate | 奥锐特药业股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| WO-2022150574-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | CORNELL UNIVERSITY (US) | 2022-07-14 | — | — | WO | disclosed |
| CN-114524804-A | Synthetic method of 2-amino-3-halogenated indole derivative | 广西大学 | 2022-05-24 | — | — | CN | disclosed |
| CN-109180554-B | Methylation reaction method | 广东石油化工学院 | 2022-04-29 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240132480-A1 | INHIBITORS OF MYCOBACTERIUM TUBERCULOSIS LIPOAMIDE DEHYDROGENASE | DLD, GCDH, DLAT | PRKCI 3276/4885CYP2A6 2173/4885MAPT 3611/4885 |
| US-20230382910-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | TRPV1, SCN3A, KCNN3 | PRKCI 2545/4885CYP2A6 716/4885MAPT 2089/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.